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95% CI 1.53e4.21, P¼0.0003, TSA-adjusted CI 0.27e21.75). In a clinical context, one must balance arguments for using NMBA when performing tracheal intubation.
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Editor's key points
This Cochrane review evaluates the effects of avoiding or using neuromuscular blocking agents on adverse events and difficulty in airway management. The results suggest that avoidance of neuromuscular blocking agents is associated with increased difficulty in intubation, and an increased risk of upper airway injury. The quality of evidence was rated as moderate to low. Large, high-quality trials are needed to examine the effects on airway injury, serious adverse events and mortality.
The use of neuromuscular blocking agents (NMBA) to facilitate tracheal intubation is a widely accepted procedure. Direct laryngoscopy stimulates the oropharynx and activates oropharyngeal reflexes. However, the use of NMBA will inhibit muscular contractions and improve conditions for tracheal intubation. 1 Due to adverse effects the use of NMBA may be undesirable. Both depolarising and non-depolarising NMBA may have side effect as anaphylaxis, cardiovascular effects related to histamine release or sympathomimetic properties, bronchospasm and prolonged paralysis. Depolarising NMBA may specifically cause muscle pain, increased serum potassium, malignant hyperthermia and increased intraocular pressure. 2 Thus, on the one hand, the use of NMBA may be associated with minor or (rare) serious adverse events (SAEs), but, on the other hand, cohort studies 3, 4 have demonstrated that avoiding neuromuscular blocking drugs may be an independent risk factor for difficult and failed tracheal intubation. Difficulties with tracheal intubation (DTI) by direct laryngoscopy can cause serious soft tissue damage 5 and DTI may be the principal causes of hypoxemic death and brain damage in relation to anaesthesia. 6 A review identified difficult airway management as the main cause of death and severe morbidity related to anaesthesia. 7 The risk of DTI may be reduced by choosing an induction strategy including, or avoiding, NMBA for facilitating tracheal intubation. This is a co-publication of a Cochrane Review. 8 We evaluated the effect of not using NMBA vs use of NMBA on difficulty of tracheal intubation by direct laryngoscopy. We addressed relevant clinical outcomes, conducted subgroup and sensitivity analyses, assessed the role of bias, and applied trial sequential analysis (TSA) to examine the level of evidence for this intervention.
Methods
This review follows the recommendations of the Cochrane Collaboration. It is based on our published Cochrane protocol 9 and Cochrane Review. 8 We included randomised controlled trials (RCTs) of participants aged !14 yr who underwent surgery and (attempt of) tracheal intubation by direct laryngoscopy. The participants were randomised to avoidance of NMBA (¼ intervention) or use of NMBA (¼ control) for facilitation of tracheal intubation. We defined use of NMBA as the control as it is traditionally considered standard for tracheal intubation by direct laryngoscopy, while avoidance of NMBA was defined as the experimental intervention.
Primary outcomes
(1) Difficult tracheal intubation. As there is no international consensus on an intubation difficulty score, the definitions of a DTI presented in the individual articles were accepted. If the authors defined a difficult laryngoscopy by the Cormack and Lehane 10 or modified Cormack and Lehane score, 11 as a difficult intubation, we included and reported the Cormack and Lehane score as the outcome measure. Difficult laryngoscopy is a surrogate outcome for a DTI. Therefore, if a trial reported both an intubation score and the Cormack and Lehane score based on the same population in the same assessment, only the intubation score was extracted for outcome assessment.
(2) Overall mortality. We used the longest follow-up data from each trial. (3) One or more events of upper airway discomfort or injury (e.g. sore throat, hoarseness, vocal cord lesion, minor pharyngeal injury).
Secondary outcomes (4) One or more major SAE: pulmonary aspiration, brain and heart injuries (e.g. caused by anoxia, hypotension, bradycardia, or tachycardia during tracheal intubation). (5) Difficult laryngoscopy, defined by Cormack and Lehane score 10 or modified Cormack Lehane score.
11
We evaluated the validity and design characteristics of each trial. To draw conclusions on the overall risk of bias for an outcome it was necessary to evaluate the trials for major sources of bias, also defined as domains. We used the risk of bias table described in the Cochrane Handbook for Systematic Reviews of Interventions section 8.5 12 as a tool for assessing risk of bias in included trials. We assessed the following risk of bias domains: allocation sequence generation, allocation concealment, blinding of participants and investigators, blinding of outcome assessment, incomplete outcome data, selective outcome reporting, and sponsor bias. We defined the trials as having low risk of bias only if they adequately fulfilled all the above-mentioned domains. Publication bias occurs when the publication of research results depends on their nature and direction. 13 We examined this by providing funnel plots (Supplementary material, Fig. S1 ) in order to detect either publication bias or a difference between small and large studies ('small study effects'), expressed by asymmetry.
14 In some trials, the patients were randomised to multiple intervention and control groups or both (more than two groups, as in dose-finding studies). We combined all relevant experimental intervention groups of the trials into a single intervention group, and combined all relevant control groups into a single control group. 12 
Statistical analysis
We used Review Manager (RevMan) [Computer program]. Version 5.3.5 Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014 for statistical analysis. Most often, a dichotomous outcome measure was used to assess whether an intubation was difficult or not. We reported all dichotomous outcomes as risk ratios (RR) with 95% confidence intervals (CI). For mortality, which we expected to be a rare outcome, we calculated the Peto odds ratio. We used D 2,15 and the I 2 statistic to describe heterogeneity among the included trials. 16 We used both a random effects model and a fixed effect model. In case of discrepancy between the two models, we report both results; otherwise, we report the random effects model. We performed the following subgroup analyses of our primary outcomes: (1) comparison of the subgroups using depolarising with non-depolarising NMBA; (2) comparison of the subgroups with or without remifentanil or alfentanil; (3) comparison of the subgroups with or without local anaesthetic drug; (4) comparing the subgroups of trials using anticipation of a difficult airway as an inclusion criterion with those that did not use difficult airway as an inclusion criterion. If analyses of various subgroups with a binary outcome were significant, we performed a test of interaction. 17 We considered P<0.05 to be indicative of significant interaction between no use of NMBA effect on DTI and the subgroup category. 12 
TSA
In a single trial, interim analysis increases the risk of type I errors. To avoid type I errors, group sequential monitoring boundaries 18 were applied to decide whether a trial could be terminated early because of a sufficiently small P-value, that is, the cumulative Z-curve crosses the monitoring boundary. Sequential monitoring boundaries can also be applied to metaanalyses, called trial sequential monitoring boundaries. In TSA, the addition of each trial in a cumulative meta-analysis is regarded as an interim meta-analysis and helps to decide whether additional trials are needed. 19e22 The idea in TSA is that if the cumulative Z-curve crosses a boundary, a sufficient level of evidence is reached, and no further trials may be needed. However, there is insufficient evidence to reach a conclusion if the Z-curve does not cross a boundary or does not surpass the required information size. To construct the trial sequential monitoring boundaries, the required information size is needed and will be calculated as the least number of participants needed in a well-powered single trial. 19, 22, 23 We adjusted the required information size for heterogeneity with a D 2 diversity adjustment factor. 15 We applied TSA as it prevents an increase in the risk of type I error (<5%) resulting from potential multiple updating and testing on accumulating data whenever new trial results are included in a cumulative meta-analysis, 19, 20 and provides us with important information to estimate the level of evidence of the experimental intervention. 19e21 Additionally, TSA provides confidence intervals adjusted for sparse data and repetitive testing (TSA-adjusted CI) in cumulative meta-analysis and important information regarding the need for additional trials and the required information size. 15, 22 We applied trial sequential monitoring boundaries according to an information size calculated for an a priori 20% relative risk reduction of difficult or failed intubation, suggested by the trials with lowrisk of bias, 15, 22 and an intervention effect suggested by the 95% confidence limit closest to 1 in the traditional randomeffects meta-analysis.
GRADE
We used the principles of the Grades of Recommendation Assessment, Development and Evaluation (GRADE) system 24, 25 to assess the quality of the body of evidence associated with specific outcomes. The GRADE approach is based on the extent to which one can be confident that an estimate of effect or association reflects the item being assessed. The quality considers: (1) within study risk of bias (methodological quality); (2) the directness of the evidence; (3) heterogeneity of the data; (4) precision of effect estimates; and (5) risk of publication bias.
Results

Description of trials
We identified 4400 references through electronic and manual search. The search was updated January 11, 2017. After excluding duplicate reports, we screened the abstracts of 2822 references. We obtained 37 publications for full text extraction. Thirty-four RCTs met our inclusion criteria 26e59 (Supplementary 
Risk of bias
We performed the risk of bias assessment of the trials using the previously described criteria. Four trials were judged as low risk of bias in all domains. 38, 45, 47, 48 Table 2 reports the bias risk assessments. In our assessment of potential reporting bias, we provided funnel plots of our primary outcomes. The plots did not express asymmetry, thus not indicating publication bias (Supplementary material, Fig. S2 ).
Effects of interventions
See our main results on in the summary of findings table (Table 3 ) grading the quality of the evidence, including imprecision, according to GRADE. Upper airway discomfort or injury (Fig. 2, Supplementary  material, Fig. S4) Only one trial reporting on upper airway discomfort or injury was categorised with overall low risk of bias. When including all trials, events of upper airway discomfort or injury were described in seven trials 29 
24,25
Mortality
None of the trials reported mortality.
Secondary outcomes
Difficult laryngoscopy (Fig. 3) Only one trial was categorised with overall low risk of bias. Among all trials where the conditions for laryngoscopy were reported a total of 1308 participants were included. Among 740 participants undergoing tracheal intubation without the use of NMBA, a crude proportion of 7.2% (n¼53; 95% CI 5.6e9.0%) had a difficult laryngoscopy. Of the 568 participants intubated using NMBA the proportion of difficult laryngoscopy was 3.3% (n¼19; 95% CI 2.1e4.8%). Avoiding NMBA was significantly associated with difficult laryngoscopy, (random-effects model, 
One or more major SAEs
One study reported SAEs. 39 A 29-yr-old man, 100 kg, ASA physical status I, experienced two of these events (tachycardia, with heart rate 85e150 beats min À1 , and bronchospasm) within 30 s of administration of 2.0 mg kg À1 ORG 9487 (rapacuronium). It was followed by erythema of the arms, shoulders, and face. The bronchospasm was treated with salbutamol, and all symptoms gradually subsided.
Subgroup analyses of primary outcomes
In our subgroup analyses concerning a DTI, the use of remifentanil, alfentanil, or local anaesthesia did not change our primary findings that avoidance of NMBA was significantly associated with a DTI. However, our subgroup analyses suggest that even though the risk of DTI was increased with no use of NMBA for both using and not using local anaesthesia, the risk was significantly lesser increased when using local anaesthesia (RR¼1.90 vs 6.26). Likewise, in the subgroup analysis of trials excluding participants with expected difficult intubation avoiding NMBA increase the risk of a difficult intubation (Supplementary material, Appendix 1). We planned to explore possible causes of heterogeneity by performing meta-regression analyses. However, because of the low degree of heterogeneity in trials with low risk of bias concerning DTI we did not perform the assessment.
Explorative outcomes
Explorative outcomes: difficult tracheal intubation: 'a bestcase scenario'
A total of 18 trials were dose-finding studies including more interventions or control groups, or both. 26,27,39e44,47e49,51,53e58 In the attempt to estimate the appropriate level of intervention or adjuvant drugs, or both, these trials may include intervention or control groups, or both, where the participants were suboptimally anaesthetised. We therefore performed a supplementary sensitivity analysis of a 'best-case scenario'. Here, the dose finding studies were only represented by the control and intervention group with the lowest prevalence of difficult intubation. Among 1180 participants undergoing tracheal intubation without the use of NMBA, a crude proportion of 25.0% (n¼295; 95% CI 22.9e27.5%) had a DTI. Of the 1230 participants intubated with the use of NMBA, the crude proportion of DTI was 3.4% (n¼42; 95% CI 2.5e4.4%). Avoidance of NMBA significantly increased the risk of a DTI with direct laryngoscopy with a risk ratio of 5.99 (95% CI 3.46e10.38; P<0.0001, NNTH¼4.4, I 2¼ 57%).
Explorative outcomes: difficult tracheal intubation: excluding dose-finding studies
In our attempt to exclude comparisons of suboptimal anaesthetic dosing regimens, we performed a sensitivity analysis excluding all dose finding trials. Thus, 16 trials having one intervention group and one control group were included. 28e38, 45, 46, 50, 52, 59 Among 769 participants undergoing tracheal intubation without the use of NMBA, a crude proportion of 15.5% (n¼119; 95% CI 13.3e18.0%) were intubated with difficulties. Of the 767 participants intubated with the use of NMBA, the crude proportion of DTI was 4.2% (n¼32; 95% CI 3.0e5.6%). Avoidance of NMBA significantly increased the risk of a DTI with a risk ratio of 3.40 (95% CI 1.63e7.10; P¼0.001, NNTH¼8.8, I 2¼ 59%).
Explorative outcomes: difficult tracheal intubation: funding from pharmaceutical industry
We identified 10 trials that reported funding from pharmaceutical industry. 27,34e36,39,41,43,51,53,58 In our attempt to identify any potential bias caused by industrial funding we performed a sensitivity analysis comparing trials receiving industrial funding with the remaining trials. We included all trials receiving industrial funding, not distinguishing between the types of funding the studies had received. In the 10 trials reporting industrial funding, we found a significant association between avoidance of NMBA and DTI, RR 4.10 (95% CI 2.67e6.31, P¼0.003, I 2 ¼64%). The remaining trials with no industrial funding also showed a significant association between avoiding NMBA and DTI, RR 5.33 (95% CI 3.16e8.98, P<0.00001, I 2 ¼68%). There was no significant subgroup difference (P¼0.45).
Discussion
Our systematic review suggests that avoidance of NMBA is associated with an increased risk of both a DTI and upper airway discomfort or injury. Our TSA demonstrated firm evidence for a harmful effect in the traditional meta-analysis on the proportions of both DTI and upper airway discomfort and injury when the significance level is adjusted for repetitive testing and sparse data in a cumulative meta-analysis. In the trials describing the conditions for laryngoscopy our metaanalysis demonstrated that avoiding NMBA was associated with a difficult laryngoscopy. However, because of inadequate information size, our TSA could not demonstrate firm evidence for a harmful effect of avoiding NMBA on upper airway discomfort or injury. Mortality was unreported in all trials and only one trial reported an episode of an (S)AE related to the use of NMBA. 39 To our knowledge there is no previous systematic review including meta-analyses of trials comparing avoidance of NMBA with use of NMBA for tracheal intubation. However, a narrative review 61 concluded that the literature describes successful techniques to intubate the trachea without the use of neuromuscular blocking agents under general anaesthesia. Further, these authors conclude that the techniques offer a useful alternative when these drugs are either contraindicated or undesirable. Another narrative review 62 concludes that induction of anaesthesia without the use of NMBA, but in combination with remifentanil provides acceptable conditions for tracheal intubation. Both reviews include several dose-finding trials where none of the patients in the different intervention groups were administered NMBA. Thus, it was impossible to compare avoiding vs using NMBA for tracheal intubation. Based upon the findings from specific drug combinations and concentrations, the authors concluded that induction without the use of NMBA might offer (almost) perfect or good conditions for intubation.
In large observational studies and reviews on difficult airway management, the fractions of DTIs range from 2% to 7%. 63e65 This agrees with our findings on the overall proportion of difficult intubation in patients who are intubated using NMBA. The crude proportion was 4.7% in trials with low risk of bias and 8.1% in all trials. However, in patients undergoing tracheal intubation without the use of NMBA the corresponding crude proportions were considerably higher: 56.3% in trials with low risk of bias and 24.2% in all trials. These latter proportions are not in accordance with experiences from everyday clinical practice and several of the trials may therefore have included suboptimal dosing regimens. We speculate that some of the dose finding trials may include intervention groups with clinically unacceptable dosing regimens that may contribute to an unrealistically increased risk of DTI. We therefore performed two post hoc sensitivity analyses. First, we evaluated a 'best case scenario' where the dose finding trials were represented only by the control and intervention group with the lowest incidence of difficult intubation. In our second sensitivity analysis, we excluded all dose finding trials, leaving all trials with a single intervention group and a single control group in our meta-analysis. In both sensitivity analyses, avoiding NMBA still significantly increased the risk of a DTI. Another possible explanation for the increased crude proportion of DTI in patients induced without NMBA may be that the majority of the included trials used a (modified) intubation score according to Viby-Mogensen and colleagues. 60, 66 This was based on information on jaw mobility, reaction to insertion of the tracheal tube and cuff inflation (diaphragmatic movement/coughing), or both. These are reasonable elements when describing the ideal conditions for intubation, though they may be affected even in successful everyday clinical airway management without 'truly' experiencing difficulties. Thus, good clinical research practice score may be very sensitive and enforces the difference between the ideal and a clinical acceptable intubation. The trials reporting conditions for laryngoscopy described by Cormack and Lehane 10 report an outcome measure traditionally used in studies dealing with difficult airway management. In our assessment, the crude proportions of difficult laryngoscopy in the intervention groups may be more recognisable and in accordance with the frequency of difficulties experienced in clinical practice and reported in the literature, as 4.2% among all trials and 7.2%, in trials with low risk of bias, who were intubated without NMBA, had a difficult laryngoscopy. One review reports on various causes for postoperative sore throat, 67 and tracheal intubation without the use of NMBA is stated as a potential risk factor for sore throat. Although this study is presented as a systematic review, only one study 30 from our review was included. Furthermore, there was no bias assessment, and the review did not include any meta-analyses. This review reported postoperative sore throat with a prevalence of up to 62%. In a Cochrane review on lidocaine for preventing postoperative sore throat, 68 the crude prevalence of sore throat was 20e30% pending the use of lidocaine. In our assessment, the crude prevalence was 33%.
Limitations and quality of evidence
About half of the included trials were using a (modified) intubation score according to "Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents" (GRPC-score) by Viby-Mogensen and colleagues. 60, 66 Further, a major part of the remaining trials used intubation scores where many of the elements from the GRPC-score were used. Thus, to some extent there was agreement across the included trials on how to define DTI. Even though the trials used a defined outcome in accordance with what is recommended in research concerning NMBA, it differs from the definitions traditionally used in research on difficult airway management. 4, 69 Although, there is a lack of consensus in the literature, these definitions often describe multiple (unsuccessful) attempts at intubation, shift to more advanced intubation techniques, or other personnel performing the airway management. 64, 69, 70 One must therefore bear in mind that our primary outcome may not reflect a situation that most clinicians consider a real difficult intubation, threatening the patient's life or health. Thus, there is a substantial degree of indirectness concerning our primary outcome describing DTI. Regarding upper airway discomfort and injury, the outcome measures varied in the various trials. Likewise, by whom, how, and when the outcome measure was evaluated differed or was not clearly stated in some of these trials. The potential heterogeneity of the outcome definitions across the included trials, especially concerning upper airway injury and discomfort must be considered when interpreting our results in a clinical context. We present our main results on all the investigated outcomes in the summary of findings tables (Table 1 ) grading the quality of the evidence according to GRADE, 24, 25 stressing the meta-analyses results originating from trials with overall low risk of bias. Between-trial heterogeneity varied from absent to substantial in the various meta-analyses concerning our different outcomes. This may emphasise the bias risk and the diversity of the dose finding regimens in the different trials, using substantially different combinations of adjuvant drugs and NMBA. Further, the minor differences in definitions of a DTI may in some degree contribute to the heterogeneity. In contrast, there was no between-trial heterogeneity regarding direct laryngoscopy which may be explained by a well-defined outcome measure 10 retrievable from all 13 trials.
We calculated TSA-adjusted CIs considering sparse data and multiple testing because of potentially repeated updates of the cumulative meta-analyses to control the risk of random errors and to prevent premature statements of superiority of one intervention compared with another. 15,21e23,71,72 TSA revealed that all our meta-analyses of the primary outcomes have a very low degree of impression, hereby indicating a low risk of random error. In the individual RCTs of this review, it is often emphasised that the incidence of disadvantages of NMBA may be a major reason for avoiding NMBA in airway management. It was a noticeable limitation that the evaluation of the effect of avoidance of NMBA compared with the use of NMBA on the occurrence of (S)AE is virtually absent. None of the trials evaluated the effect on mortality (short-or long-term) and only one trial the effect on other types of (S)AE reporting one (S)AE. After completing this review, we do not know whether the lack of reported side effects is as a result of 'silence' because (S)AEs were not observed/registered or actually 'absent'.
In most of the included trials the cut off values defining a DTI were clearly stated. However, in five trials, 28, 33, 44, 53, 56 different composite scores were used without defined cutoffs. In assessing these trials, we used the underlying references or comparable scores to define a cut off value enabling us to include the trials in our meta-analyses. Thus, some degree of interpretation of the outcome measures was necessary and, as a consequence, our assessments may have introduced bias. Nevertheless, we believe that this categorisation was justifiable considering the existing literature and we therefore consider the risk of introducing bias as low.
In six trials, 35, 38, 45, 46, 49, 55 the authors excluded a few patients from their assessments if tracheal intubation failed. We consider these patients as truly difficult to intubate and therefore we chose to include them in our meta-analyses. This may have introduced bias; however, a sensitivity analysis excluding these patients from our meta-analyses did not change the conclusion.
Conclusion
This review supports that the use of NMBA may create better conditions for tracheal intubation in clinical practice than avoidance of NMBA. In trials with an overall low risk of bias, there was a significantly increased risk of DTI with no use of NMBA with a RR of 13.3 and for all included trials this association was confirmed with a RR of 5.0. The results were characterised by indirectness concerning our primary outcome describing DTI. Based on the defined outcomes in the included trials, our primary outcome may not reflect a situation that most clinicians consider to be a clinically important DTI where the patient's life or health may be threatened. Thus, we could not conclude with certainty that the avoidance of NMBA was associated with a clinically important or serious difficult intubation. A difficult laryngoscopy, as defined by Cormack and Lehane, may be a reasonable surrogate for a clinically serious difficult airway. Our results indicate that avoiding NMBA increases the risk of a difficult laryngoscopy, but after TSA adjustment of the CI, firm evidence could not be established. Concerning our other primary outcome, 'events of upper airway discomfort or injury', there were only few data from trials with low risk of bias. Among all trials, there was a firm and significant risk of upper airway discomfort or injury when avoiding NMBA. Of specific notice is the fact that the evaluation of the effect of avoidance of NMBA compared with the use of NMBA on the occurrence of SAE is virtually absent as none of the trials evaluated the effect on mortality (short-or longterm). There is implication for future research focusing on the impact of avoiding NMBA on the prevalence of severe intubation difficulties and difficult laryngoscopy as categorised by Cormack and Lehane. In addition, large trials with low risk of bias describing upper airway injury and discomfort, and other SAEs and mortality are needed.
In conclusion, in a clinical context one must balance arguments for using or not using NMBA when performing tracheal intubation.
